Better Buy: AbbVie vs. Johnson & Johnson

Many large pharmaceutical companies fall into the category of widow-and-orphan stocks -- stocks that have a relatively high dividend yield and pose very low risks to investors. An investment in a widow-and-orphan stock is intended to grow over time, provide income, and generally go untouched for long periods. When evaluating companies offering that kind of safety, traditional metrics sometimes fail to capture some of the most important factors of the company.

AbbVie (NYSE: ABBV) and Johnson & Johnson (NYSE: JNJ) are two pharmaceutical companies that fit the widow-and-orphan description. So which is a better buy right now? 

Image source: Getty Images.

Continue reading

Source Fool.com